elritercept
KER050-MD-201
Phase 2 small_molecule active
Quick answer
elritercept for Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS). is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active